Next Article in Journal
Optimization and Evaluation of a Chitosan/Hydroxypropyl Methylcellulose Hydrogel Containing Toluidine Blue O for Antimicrobial Photodynamic Inactivation
Next Article in Special Issue
To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies
Previous Article in Journal
Recombinant Lipases and Phospholipases and Their Use as Biocatalysts for Industrial Applications
Previous Article in Special Issue
AGEs-Induced IL-6 Synthesis Precedes RAGE Up-Regulation in HEK 293 Cells: An Alternative Inflammatory Mechanism?
Open AccessReview

Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases

1
Institute of Food and Bioresources Technology, Dedan Kimathi University of Technology, 10100 Nyeri, Kenya
2
School of Nutrition and Health Sciences, College of Public Health and Nutrition, Taipei Medical University, 250 Wu-Xing Street, 110 Taipei, Taiwan
3
Community Health Nursing Department, Faculty of Health Sciences, University of Swaziland, H100 Mbabane, Swaziland
*
Author to whom correspondence should be addressed.
Academic Editor: Kamal D. Moudgil
Int. J. Mol. Sci. 2015, 16(9), 20841-20858; https://doi.org/10.3390/ijms160920841
Received: 19 June 2015 / Revised: 19 August 2015 / Accepted: 25 August 2015 / Published: 1 September 2015
(This article belongs to the Special Issue Mechanism of Action and Applications of Cytokines in Immunotherapy)
Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A–F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn’s disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed. View Full-Text
Keywords: Th17; IL-17; probiotics; inflammatory bowel diseases; inflammation Th17; IL-17; probiotics; inflammatory bowel diseases; inflammation
MDPI and ACS Style

Owaga, E.; Hsieh, R.-H.; Mugendi, B.; Masuku, S.; Shih, C.-K.; Chang, J.-S. Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases. Int. J. Mol. Sci. 2015, 16, 20841-20858.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop